Global Vaccines Market is Projected to Grow at a CAGR of 7.0% During the Forecast Period, 2019-2024 - ResearchAndMarkets.com

DUBLIN--()--The "Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, shingles, Rabies), Route (IM, SC, ID, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The global vaccines market is projected to reach USD 58.4 billion by 2024 from USD 41.7 billion in 2019, at a CAGR of 7.0% during the forecast period.

The key factors driving the growth of this market include the high prevalence of infectious diseases, growing support for vaccine R&D, investments in vaccine development, and rising focus on immunization. However, the huge capital investments required for developing vaccines may restrain market growth.

The pneumococcal disease segment will continue to dominate the vaccines market during the forecast period.

On the basis of disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, and other disease indications. The pneumococcal disease segment accounted for the largest share of the vaccines market in 2018. The large share of this segment can be attributed to the high incidence of pneumococcal disease and increasing government investments in pneumococcal vaccination programs.

By type, the monovalent vaccines segment accounted for the larger share of the vaccines market in 2019.

On the basis of type, the vaccines market is segmented into monovalent and multivalent vaccines. The monovalent vaccines segment accounted for the largest share of the vaccines market in 2018. The large share of this segment can be attributed to the rising prevalence of diseases and increasing government & non-government initiatives to promote immunization.

The market in Asia is projected to witness the highest growth rate during the forecast period (2019-2024).

Asia is projected to register the highest growth during the forecast period. Growing company investments in Asian countries and rising government support for vaccine development are some of the key factors supporting the growth of the vaccines market in Asia.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the vaccines market. The report analyzes the market based on technology, type, disease indication, route of administration, patient type, and region.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the vaccines market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of vaccines across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the vaccines market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the vaccines market.

Key Topics Covered:

1 Introduction

1.1 Objectives of the Study

1.2 Market Definition

1.3 Market Scope

1.4 Currency

1.5 Limitations

1.6 Stakeholders

2 Research Methodology

2.1 Research Approach

2.2 Market Size Estimation

2.3 Data Triangulation Approach

2.4 Market Share Analysis

2.5 Assumptions for the Study

3 Executive Summary

4 Premium Insights

4.1 Vaccines Market Overview

4.2 North America: Vaccines Market, By Technology (2018)

4.3 Geographical Snapshot of the Vaccines Market

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.2 Restraints

5.2.3 Opportunities

5.2.4 Challenges

6 Industry Insights

6.1 Regulatory Landscape

6.1.1 North America

6.1.2 Europe

6.1.3 Asia

6.1.4 RoW

6.2 Key Pipeline Products

6.3 New Vaccine Opportunities

6.3.1 HIV

6.3.2 Malaria

6.3.3 Zika

6.3.4 Ebola

7 Vaccines Market, By Technology

7.1 Introduction

7.2 Conjugate Vaccines

7.3 Inactivated & Subunit Vaccines

7.4 Live Attenuated Vaccines

7.5 Recombinant Vaccines

7.6 Toxoid Vaccines

8 Vaccines Market, By Type

8.1 Introduction

8.2 Monovalent Vaccines

8.3 Multivalent Vaccines

9 Vaccines Market, By Disease Indication

9.1 Introduction

9.2 Pneumococcal Disease

9.3 DTP

9.4 Influenza

9.5 HPV

9.6 Meningococcal Disease

9.7 Polio

9.8 Hepatitis

9.9 Rotavirus

9.10 MMR

9.11 Varicella

9.12 Herpes Zoster

9.13 Other Disease Indications

10 Vaccines Market, By Route of Administration

10.1 Introduction

10.2 Intramuscular and Subcutaneous Administration

10.3 Oral Administration

10.4 Other Routes of Administration

11 Vaccines Market, By Patient Type

11.1 Introduction

11.2 Pediatric Patients

11.3 Adult Patients

12 Vaccines Market, By Region

12.1 Introduction

12.2 North America

12.3 Europe

12.4 Asia

12.5 Rest of the World

13 Competitive Landscape

13.1 Overview

13.2 Market Share Analysis

13.3 Competitive Leadership Mapping

13.4 Competitive Situation and Trends

14 Company Profiles

14.1 Glaxosmithkline PLC

14.2 Pfizer, Inc

14.3 Merck & Co., Inc

14.4 Sanofi Pasteur SA

14.5 CSL Limited

14.6 Emergent Biosolutions, Inc

14.7 Johnson & Johnson

14.8 Astrazeneca

14.9 Serum Institute of India Pvt., LTD

14.10 Bavarian Nordic

14.11 Mitsubishi Tanabe Pharma Corporation

14.12 Daiichi Sankyo Company, Limited

14.13 Panacea Biotec, LTD

14.14 Biological E

14.15 Bharat Biotech

14.16 Other Companies

14.16.1 Sinovac Biotech, LTD

14.16.2 Incepta Vaccine, LTD

14.16.3 Valneva SE

14.16.4 Vbi Vaccines Inc

14.16.5 Pt Bio Farma (Persero)

For more information about this report visit https://www.researchandmarkets.com/r/gf7pje

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900